Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.